Indication
Malignant Peripheral Nerve Sheath Tumor
9 clinical trials
9 products
5 drugs
Clinical trial
A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue SarcomasStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Drug
SelinexorClinical trial
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath TumorStatus: Recruiting, Estimated PCD: 2024-09-14
Product
Oncolytic Measles VirusClinical trial
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Nanoplexed Poly I:C BO-112Product
NivolumabClinical trial
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)Status: Active (not recruiting), Estimated PCD: 2019-06-30
Product
DoxorubicinProduct
IfosfamideProduct
PazopanibClinical trial
BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastStatus:
Drug
DeltaRex-GClinical trial
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-31
Product
MetarrestinClinical trial
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Product
TelaglenastatClinical trial
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-07-17
Product
DexrazoxaneDrug
R-CHOPClinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Drug
LurbinectedinDrug
T-VEC